NIA‐AA Research Framework: Toward a biological definition of Alzheimer's diseaseClifford R. Jack, Nina Silverberg, David A. Bennett et al.|Alzheimer s & Dementia|2018Cited by 10.4k
Two Phase 3 Trials of Bapineuzumab in Mild-to-Moderate Alzheimer's DiseaseStephen Salloway, H. Robert Brashear, Reisa A. Sperling et al.|New England Journal of Medicine|2014Cited by 2k
Spread of pathological tau proteins through communicating neurons in human Alzheimer’s diseaseJacob W. Vogel, Erin Householder, Enchi Liu et al.|Nature Communications|2020Cited by 539
Amyloid-related imaging abnormalities in patients with Alzheimer's disease treated with bapineuzumab: a retrospective analysisReisa A. Sperling, Michael Grundman, Stephen Salloway et al.|The Lancet Neurology|2012Cited by 510
Polygenic risk of Alzheimer disease is associated with early- and late-life processesElizabeth C. Mormino, Robert A. Koeppe, Reisa A. Sperling et al.|Neurology|2016Cited by 196